Rogers Corporation designs, develops, manufactures, and sells engineered materials and components in the United States, other Americas, China, other Asia Pacific countries, Germany, Europe, the Middle East, and Africa. It operates through Advanced Electronics Solutions (AES), Elastomeric Material Solutions (EMS), and Other segments. The AES segment offers circuit materials, ceramic substrate materials, busbars, and cooling solutions for applications in electric and hybrid electric vehicles, automotive, aerospace and defense, renewable energy, wireless infrastructure, mass transit, industrial, connected devices, and wired infrastructure markets. This segment sells its products under the curamik, ROLINX, RO4000 series, RO3000 series, RT/duroid, CLTE series, TMM, AD series, DiClad series, CuClad series, Kappa, COOLSPAN, TC series, IsoClad series, MAGTREX, IM series, 2929 Bondply, SpeedWave Prepreg, RO4400/RO4400T series, and Radix trade names. The EMS segment provides engineered material solutions, including polyurethane and silicone materials used in cushioning, gasketing, sealing, and vibration management applications; customized silicones used in flex heater and semiconductor thermal applications; and polytetrafluoroethylene and ultra-high molecular weight polyethylene materials used in wire and cable protection, electrical insulation, conduction and shielding, hose and belt protection, vibration management, cushioning, gasketing and sealing, and venting applications. This segment sells its products under the PORON, BISCO, DeWAL, ARLON, eSorba, XRD, Silicone Engineering, and R/bak trade names. The Other segment offers elastomer components under the ENDUR trade name for applications in the general industrial market, as well as elastomer floats under the NITROPHYL trade name for level sensing in fuel tanks, motors, and storage tanks applications in the general industrial and automotive markets. The company was founded in 1832 and is headquartered in Chandler, Arizona.
Roche's Crossroads | Explore Roche's strategic position as it navigates growth challenges in key segments while leveraging its strong market presence and robust balance sheet |
Obesity Market Entry | Delve into Roche's ambitious foray into the competitive obesity treatment landscape, analyzing its pipeline assets and their potential market impact |
Diagnostic Dominance | Learn how Roche's expertise in diagnostics innovation could drive future growth, capitalizing on industry trends and synergies with its pharmaceutical division |
Financial Outlook | Analysts project a challenging near-term with a Hold rating and price targets around CHF 272-275, reflecting cautious optimism amid competitive pressures |
Metrics to compare | ROG | Sector Sector - Average of metrics from a broad group of related Technology sector companies | Relationship RelationshipROGPeersSector | |
---|---|---|---|---|
P/E Ratio | −19.6x | −15.4x | 11.9x | |
PEG Ratio | 0.09 | 1.07 | 0.01 | |
Price/Book | 1.1x | 3.5x | 2.4x | |
Price / LTM Sales | 1.6x | 3.7x | 2.2x | |
Upside (Analyst Target) | 13.9% | 8.2% | 20.2% | |
Fair Value Upside | Unlock | −4.0% | 5.4% | Unlock |